Search Patents
  • Publication number: 20220168235
    Abstract: The present invention relates to cannabigerol (CBG), a cannabinoid, for use in the treatment of chronic insomnia, sleeplessness and “staying in sleep” discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and/or hyperactivity. The invention further relates to a pharmaceutical formulation comprising cannabinoid Cannabigerol (CBG) and cannabinoid Cannabinodiol (CBND) for use in the treatment of chronic insomnia, sleeplessness and “staying in sleep” discomfort, subjective and objective sleep disorders, primary and secondary sleep disorders, insomnia related symptoms, depression, anxiety, and/or hyperactivity, preferably wherein the ratio of CBG:CBND by weight is between 10:1 and 1:10.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 2, 2022
    Inventor: Ronald Johannes GLAS
  • Publication number: 20140039043
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: February 6, 2014
    Applicant: GW Pharma Limited
    Inventor: GW Pharma Limited
  • Publication number: 20080031977
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Application
    Filed: June 8, 2007
    Publication date: February 7, 2008
    Applicant: GW Pharma Limited
    Inventors: Richard Musty, Richard Deyo
  • Patent number: 8481085
    Abstract: The present invention relates to the use of cannabigerol (CBG) type compounds and derivatives thereof in the treatment of mood disorders.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: July 9, 2013
    Assignee: GW Pharma Limited
    Inventors: Richard Musty, Richard Deyo
  • Patent number: 11040932
    Abstract: Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: June 22, 2021
    Assignee: Treehouse Biotech, Inc.
    Inventors: Thomas Smeltzer, Robert Davis, Sean Colvin, Jacob Black
  • Publication number: 20200115306
    Abstract: Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 16, 2020
    Inventors: Thomas Smeltzer, Robert Davis, Sean Colvin, Jacob Black
  • Publication number: 20210276936
    Abstract: Multiple methods of synthesizing cannabigerol are presented. Combining olivetol with geraniol derivatives are provided. Cross-coupling methods of combing functionalized resorcinols are provided. Useful intermediates are formed during such cross-coupling steps.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 9, 2021
    Inventors: Thomas Smeltzer, Robert Davis, Sean Colvin, Jacob Black
  • Publication number: 20210400895
    Abstract: The present disclosure relates to new Cannabis plants, including parts, extracts and uses thereof, comprising a cannabinoid profile enriched for total THC (i.e., ?-9-tetrahydrocannabinol (THC) and ?-9-tetrahydrocannabinolic acid (THCA)) and total CBG (i.e., cannabigerol (CBG) and cannabigerolic acid (CBGA)).
    Type: Application
    Filed: November 8, 2019
    Publication date: December 30, 2021
    Inventors: Aaron Christopher Elkins, Simone Jane Rochfort, Noel Cogan, German Carlos Spangenberg
  • Publication number: 20220000056
    Abstract: The present disclosure relates generally to new cannabis plants, including parts, extracts and uses thereof, comprising a cannabinoid profile enriched for total THC (i.e., ?-9-tetrahydrocannabinol (THC) and ?-9-tetrahydrocannabinolic acid (THCA), total CBG (i.e., cannabigerol (CBG) and cannabigerolic acid (CBGA)), and total THCV (i.e., tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA)).
    Type: Application
    Filed: November 8, 2019
    Publication date: January 6, 2022
    Inventors: Aaron Christopher Elkins, Simone Jane Rochfort, Noel Cogan, German Carlos Spangenberg
  • Publication number: 20100292345
    Abstract: The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 18, 2010
    Applicant: GW PHARMA LIMITED
    Inventor: Roger Pertwee
  • Publication number: 20160235661
    Abstract: This invention discloses various cosmetics and topical formulations comprising cannabigerol, a non-psychoactive cannabinoid. The formulation may be an anti-aging cream for day or night application, a hand and nail cream, an eye cream, an acne treatment cream or tonic, an anti-diaper rash cream, a shampoo, a conditioner, a body wash, a face wash, deodorant spray, or a lip balm formulation. These topical and cosmetic formulations have speedy wound healing, skin firming, anti-bacterial, anti-dandruff, skin soothing, and UV ray protection properties.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 18, 2016
    Inventors: Lekhram CHANGOER, George ANASTASSOV
  • Publication number: 20200188325
    Abstract: This invention discloses various cosmetics and topical formulations comprising cannabigerol, a non-psychoactive cannabinoid. The formulation may be an anti-aging cream for day or night application, a hand and nail cream, an eye cream, an acne treatment cream or tonic, an anti-diaper rash cream, a shampoo, a conditioner, a body wash, a face wash, deodorant spray, or a lip balm formulation. These topical and cosmetic formulations have speedy wound healing, skin firming, anti-bacterial, anti-dandruff, skin soothing, and UV ray protection properties.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 18, 2020
    Inventors: Lekhram Changoer, George Anastassov
  • Patent number: 9802880
    Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: October 31, 2017
    Inventors: Giovanni Appendino, María Luz Bellido Cabello De Alba, Eduardo Muñoz Blanco
  • Publication number: 20170247308
    Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
    Type: Application
    Filed: February 12, 2015
    Publication date: August 31, 2017
    Applicant: VIVACELL BIOTECHNOLOGY ESPAÑA S.L.
    Inventors: Giovanni APPENDINO, María Luz BELLIDO CABELLO DE ALBA, Eduardo MUÑOZ BLANCO
  • Publication number: 20190060251
    Abstract: A method to treat the skin condition atopic dermatitis is described in this invention. The method comprises topical application of a composition containing cannabinoids, specifically cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The method may further comprise administering chewing gum containing cannabinoids such as cannabidiol. Cannabidiol and cannabigerol may be sourced naturally or synthetically.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 28, 2019
    Inventors: Lekhram CHANGOER, George ANASTASSOV
  • Publication number: 20190060252
    Abstract: A method to treat the skin condition vitiligo is described in this invention. The method comprises topical application of a composition containing cannabinoids, in particular cannabidiol and cannabigerol, at a concentration of 3%-20% by weight of the composition onto the affected skin area of a subject in need thereof. Application may be twice (2) daily for about six (6) weeks. Cannabidiol and cannabigerol may be sourced naturally or synthetically.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 28, 2019
    Inventors: Lekhram CHANGOER, George ANASTASSOV
  • Publication number: 20220168265
    Abstract: The present invention relates to a pharmaceutical composition comprising a tetrahydrocannabivarin (THCV), wherein the composition further comprises cannabigerol (CBG) or cannabinodiol (CBND) or a mixture thereof, for use in the prevention and treatment of overweight, preferably associated with obesitas. The pharmaceutical composition according to the invention may further comprise the following additional compounds tetrahydrocannabinol (THC), or Cannabigerol (CBG) or Cannabinodiol (CBND) or a combination thereof.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 2, 2022
    Inventor: Ronald Johannes GLAS
  • Patent number: 10272051
    Abstract: A method to treat the skin condition atopic dermatitis is described in this invention. The method comprises topical application of a composition containing cannabinoids, specifically cannabidiol and cannabigerol at a concentration of 3%-20% by weight of the composition. The method may further comprise administering chewing gum containing cannabinoids such as cannabidiol. Cannabidiol and cannabigerol may be sourced naturally or synthetically.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: April 30, 2019
    Assignee: Axim Biotechnologies, Inc.
    Inventors: Lekhram Changoer, George Anastassov
  • Patent number: 10098867
    Abstract: The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: October 16, 2018
    Assignee: GW Research Limited
    Inventors: Farideh Afshin Javid, Marnie Duncan, Colin Stott
  • Publication number: 20160136128
    Abstract: The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 19, 2016
    Inventors: Farideh Javid, Marnie Duncan, Colin Stott
Narrow Results

Filter by US Classification